Company MorphoSys AG Deutsche Boerse AG

Equities

MOR2

US6177602025

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for MorphoSys AG

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Deutsche Boerse AG Other stock markets 04:56:15 2024-06-20 am EDT			5-day change	1st Jan Change
16.5 ^EUR	+0.61%		-0.60%	+96.43%

11:10am	Novartis: towards the filing of a buyout offer for MorphoSys	CF
10:20am	MorphoSys Set to Delist Following Acquisition by Novartis	MT

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Number of employees: 464

EUR in Million	2022	Weight	2023	Weight	Delta
Innovative Cancer Medicines 100.0 %	278	100.0 %	238	100.0 %	-14.37%

EUR in Million	2022	Weight	2023	Weight	Delta
United States 88.8 %	0	0.0 %	211	88.8 %	-
Europe (excluding Germany) 11.2 %	-	-	27	11.2 %	-
Asia 0.0 %	-	-	0	0.0 %	-

Managers	Title	Age	Since
Luisa Ciccarelli CTO	Chief Tech/Sci/R&D Officer	-	21-07-31
Tim Demuth CTO	Chief Tech/Sci/R&D Officer	50	22-09-30
Julia Neugebauer IRC	Investor Relations Contact	-	06-08-31
Daniel Palmacci PRN	Corporate Officer/Principal	-	20-06-30
Ann Merchant PRN	Corporate Officer/Principal	59	17-12-31
Ralf Ostendorp PRN	Corporate Officer/Principal	-	98-12-31
Günter Wellnhofer PRN	Corporate Officer/Principal	-	94-04-30
Klaus de Wall AUD	Comptroller/Controller/Auditor	-	05-05-31
Barbara Krebs-Pohl PRN	Corporate Officer/Principal	-	97-12-31
Charlotte Lohmann HRO	Human Resources Officer	54	12-05-29

Members of the board	Title	Age	Since
Sharon Curran BRD	Director/Board Member	56	19-05-21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	37,716,423	2,130,820 ( 5.650 %)	53,685 ( 0.1423 %)	5.650 %

Name	Equities	%	Valuation
NOVARTIS AG 51.00 %	19,235,376	51.00 %	1 434 M €
Adage Capital Management LP 5.011 %	1,890,000	5.011 %	141 M €
Norges Bank Investment Management 4.481 %	1,690,137	4.481 %	126 M €
RP Management LLC (Investment Management) 3.546 %	1,337,552	3.546 %	100 M €
Goldman Sachs & Co. LLC (Private Banking) 2.876 %	1,084,624	2.876 %	81 M €
Caligan Partners LP 2.805 %	1,057,962	2.805 %	79 M €
DWS Investment GmbH 2.301 %	868,004	2.301 %	65 M €
Baillie Gifford & Co. 2.215 %	835,292	2.215 %	62 M €
Union Investment Privatfonds GmbH 0.6550 %	247,044	0.6550 %	18 M €
Amundi Asset Management SA (Investment Management) 0.2832 %	106,804	0.2832 %	8 M €

Name	Equities	%	Valuation
Glazer Capital LLC 0.9610 %	1,449,853	0.9610 %	27 M €
Balyasny Asset Management LP 0.8643 %	1,303,945	0.8643 %	24 M €
UBS Financial Services, Inc. 0.7738 %	1,167,338	0.7738 %	21 M €
Aperio Group LLC 0.6747 %	1,017,852	0.6747 %	19 M €
Carlson Capital LP 0.6300 %	950,461	0.6300 %	17 M €
Tang Capital Management LLC 0.5307 %	800,705	0.5307 %	15 M €
Slotnik Capital LLC 0.4345 %	655,519	0.4345 %	12 M €
Goldman Sachs & Co. LLC 0.4216 %	636,016	0.4216 %	12 M €
Segantii Capital Management Ltd. 0.3072 %	463,466	0.3072 %	9 M €
Tudor Investment Corp. 0.2276 %	343,310	0.2276 %	6 M €

MorphoSys AG

Semmelweisstrasse 7

82152, Planegg

+49 89 899 27-0

http://www.morphosys.de

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

67.25 EUR

Average target price

58.71 EUR

Spread / Average Target

-12.69%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+34.01%	51.07B
IQVIA HOLDINGS INC.	-8.02%	38.78B
LONZA GROUP AG	+34.32%	38.61B
CELLTRION, INC.	-8.98%	27.32B
ICON PUBLIC LIMITED COMPANY	+12.56%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-19.62%	19.46B
UNITED THERAPEUTICS CORPORATION	+39.18%	13.58B
MEDPACE HOLDINGS, INC.	+31.47%	12.46B
BIO-TECHNE CORPORATION	-3.40%	11.75B

Other Biotechnology & Medical Research